Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.66 |
| ▸ | FOS | P01100 | 1/20 | 0.66 |
| ▸ | JUN | P05412 | 1/20 | 0.66 |
| ▸ | BCHE | P06276 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.59 |
| ▸ | RELA | Q04206 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27497698 | 1.00 | MAOB (0.66) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL1383790 | 1.00 | MAOB (0.66) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL29244511 | 1.00 | MAOB (0.66) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL16410054 | 0.89 | MAOB (0.57) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL3580365 | 0.86 | FOS (0.79) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL3580362 | 0.86 | FOS (0.79) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL29822711 | 0.86 | FOS (0.79) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL80786 | 0.85 | FOS (0.72) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL2632249 | 0.85 | MAOB (0.68) | MAOBFOSJUNBCHECYP1A2 | |
| SCHEMBL80787 | 0.85 | FOS (0.72) | MAOBFOSJUNBCHECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1867572-A | proteasome inhibitors and methods of use thereof | CEPHALON INC (US) | 2006-11-22 | — | — | CN | claimed |
| CN-1217943-C | New use and novel N-azabicyclo-amide derivatives | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | CN | claimed |
| CN-1423651-A | Novel use and novel N-azabicyclo-amide derivatives | ASTRAZENECA AB (SE) | 2003-06-11 | — | — | CN | claimed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160102047-A1 | SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHOD AND THE USE THEREOF | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2016-04-14 | — | — | US | disclosed |
| EP-2968308-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | Shire Human Genetic Therapies, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015009768-A1 | PHOTOPATTERNABLE MATERIALS AND RELATED ELECTRONIC DEVICES AND METHODS | POLYERA CORPORATION (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014159637-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20130150403-A1 | NUCLEAR RECEPTOR BINDING AGENTS | VA Long Beach Healthcare System (US) | 2013-06-13 | — | — | US | disclosed |
| EP-1771453-B1 | HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS | BOEHRINGER INGELHEIM INT (DE) | 2012-05-30 | — | — | EP | disclosed |
| WO-2010025235-A1 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-04 | — | — | WO | disclosed |
| CN-1217943-C | New use and novel N-azabicyclo-amide derivatives | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | CN | disclosed |
| CN-1423651-A | Novel use and novel N-azabicyclo-amide derivatives | ASTRAZENECA AB (SE) | 2003-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102047-A1 | SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHOD AND THE USE THEREOF | PNMT, TPMT, HTR3A | MAOB 385/4885FOS 2763/4885JUN 3624/4885 |
| US-20130150403-A1 | NUCLEAR RECEPTOR BINDING AGENTS | FABP3, NCOR1, NR3C2 | MAOB 2515/4885FOS 1010/4885JUN 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.